Posts

Reflection 12/6

This week we learned about Big Data and real world evidence/data and how it can ultimately revolutionize the industry. Big Data is the cumulation of health data from a multitude of sources such as  electronic health records (EHRs), medical imaging, genomic sequencing, payor records, pharmaceutical research, wearables, and medical devices. This data is sourced in a cloud and is compiled is mass volumes. The difference between this and other data compilations is that it has more data than any other, it's moving at high velocity, and it has such high variability. Big Data allows the health industry to have access to more data from many different systems in order to allow them to make more quality and information based decisions. The two major aspects that Big Data can change are that this can allow the industry to switch from fee for service to value based and it allows for more evidence based decisions that increases efficiencies. The fee for service model means that physic...

Readings for 12/5

Three Interesting Things: 1.) I find it interesting that Big Data has been there for a while and there is a mass amount of it but yet it has just started being used. The solution to the healthcare industry's problem has been right in front of them but they struggled to grasp it and convert it to useful knowledge. 2.) I think that it is interesting that an underlying problem continuously brought up in class is the "fee for service" model that is currently in the system. This problem leads to malpractice of medicine as well as over use of treatment in order to make a quick buck. Having Big Data will allow for the industry to defer from this and provide the care that is needed for the specific patient and the physicians will be compensated on this. The more positive outcomes they have the more money they will make. This will decrease medical errors and sending which will ultimately aid the systems defaults now. 3.) I think it is interesting that clinical trials have had s...

Reflection 11/29

This week we talked about ethical guidelines and regulations when it comes to human subjects volunteering in research. When it comes to research there tends to be a vague area as to what needs to be disclosed and what does not. In the past, research has gone through trials and tribulations as patients are either pleased or not with their outcomes in a research trial. Misuse of volunteerism knowledge dates all the way back to Nazi Germany. In this time research experiments took place in concentration camps where vile tests were done on "volunteers" that left them most often in harms way. As war crimes were later reviewed, boards decided that there had to be regulations put in place in order to ensure the safety of research volunteers so that law suits and criminal trials would not have to occur. The Nuremberg Code was put into place that stated ten rules to follow in terms of mostly consent and qualifications to run the trial. Then the Belmont report came out to further explai...

Readings 11/26

Three Interesting Things: 1.) I find it interesting that when researchers are looking for volunteers, they disclose all sorts of information to them in order to make sure that they have all the information they need to make their decision. This interests me because if physicians and pharmacists did this during their regular practice than they would deal with less medical errors and more efficient adherence of patients. Why is there a difference in information given if research and practice are similarly on the same level. 2.) I find that the IRB kind of relates or has similarities of a jury. They are people who cannot have connection to subjects or the conditions at hand because it will skew their review. They are all culturally diverse and full of people with totally different backgrounds. It gives a more honest review in the end as well as make the trial more efficient. 3.) I think that it is interesting that the Code of Federal Regulations uses the word reasonable so often; reaso...

Reflection 11/22/19

This week we talked about the opioid epidemic in the United States. When it comes to this crisis there is much to take into consideration. The crisis is not new and has been around for years. The crisis has come in three waves starting with the 1990's where opioid prescription numbers started to increase and this followed with a rise in overdose deaths. The second wave, in 2010, marked the rise of heroin induced deaths due to the fact that those addicted to prescriptions had to find a more readily available alternative. The third wave of 2013 was due to the fact that over dose deaths were most commonly due to synthetic opioids like fentanyl. When it comes to opioids, they have a range of uses but are mostly used for pain relief. Opioids have three levels; opiates, semi-synthetic, and synthetic. Each level is a further breakdown or derivative of the earlier. Opiates come directly from the juice of the Papaver Somniferum plant and are used to raise the pain threshold and reduce the p...

Readings for 11/21

Three Interesting Things: 1.) I think it is interesting that some patients avoid treating their pain with opioids because of the negative connotation given by the media surrounding these drugs. Although, yes, they can be addictive there are ways to manage the intake so that you can both treat your pain and not become addicted. 2.) I think that the fact that patients could have to sign a narcotic contract to ensure that they will not go to fill the prescription at another pharmacy. I think that this is an excessive way to do this but I also feel that this is the only way to keep patients honest because of people within these situations these people cannot control their need. 3.) I think that it is interesting that this article brings up the topic of having pharmacists be more intuned with their work and be more educating for their patients. We have talked about often how pharmacists should have more of a comforting position with their patients and be able to have empathy for them. ...

Potential Quiz Questions

1.) What are A of C codes? (Sept 26) 2.) Why are some classes of medical devices exempt from the 510 K versus others? (October 3) 3.) Would adding a in house pharmacist to every doctors office be more cost effective? (October 10) 4.) Would implementing pharmacists as part of a care team cause them to have to do more schooling? (November 5) 5.) Are MTM consultations covered by insurance? (November 7) 6.) How does pharmacoeconomics change the industry? (October 8)